Prostate MRI: Can we do without DCE sequences in 2013?

Diagnostic and Interventional Imaging

Volumn 94, Issue 12, 2013, Pages 1299-1311

  Puech, P ^a,b,c   Sufana Iancu, A ^a,c   Renard, B ^a   Lemaitre, L ^a,b,c  

^a Regional Hospital and University Center   (France)

^b UNIV LILLE   (France)

^c INSERM   (France)

Author keywords

Cancer; Diffusion weightedimaging (DWI); Perfusion (DCE MRI); Prostate

Indexed keywords

GADOLINIUM;

ADULT; AGGRESSIVENESS; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CASE REPORT; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; SEMINAL VESICLE; STANDARDIZATION;

CANCER; DIFFUSION-WEIGHTED-IMAGING (DWI); PERFUSION (DCE-MRI); PROSTATE;

CONTRAST MEDIA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PROSTATIC NEOPLASMS;

EID: 84895067077     PISSN: None     EISSN: 22115684     Source Type: Journal    
DOI: 10.1016/j.diii.2013.09.010     Document Type: Short Survey

References (77)

1. Tanimoto A, Nakashima J, Kohno H, Shinmoto H, Kurib-ayashi S. Prostate cancer screening: the clinical value ofdiffusion-weighted imaging and dynamic MR imaging in com-bination with T2-weighted imaging. J Magn Reson Imaging2007;25(1):146-52 [Epub 2006/12/02]. (Pubitemid 46095209)
2. Puech P, Betrouni N, Makni N, Dewalle AS, Villers A, LemaitreL. Computer-assisted diagnosis of prostate cancer using DCE-MRI data: design, implementation and preliminary results. IntJ Comput Assist Radiol Surg 2009;4(1): 1-10.
3. Puech P, Potiron E, Lemaitre L, Leroy X, Haber GP, Crouzet S, et al. Dynamic contrast-enhanced-magnetic resonance imagingevaluation of intraprostatic prostate cancer: correlation withradical prostatectomy specimens. Urology 2009;74(5):1094-9[Epub 2009/09/24].
4. Delongchamps NB, Rouanne M, Flam T, Beuvon F, Liberatore M, Zerbib M, et al. Multiparametric magnetic resonance imag-ing for the detection and localization of prostate cancer:combination of T2-weighted, dynamic contrast-enhanced anddiffusion-weighted imaging. BJU Int 2011;107(9):1411-8 [Epub2010/11/04].
5. Delongchamps NB, Beuvon F, Eiss D, Flam T, Muradyan N, Zer-bib M, et al. Multiparametric MRI is helpful to predict tumorfocality, stage, and size in patients diagnosed with unilat-eral low-risk prostate cancer. Prostate Cancer Prostatic Dis2011;14(3):232-7 [Epub 2011/03/23].
6. Quentin M, Arsov C, Rohlen S, Klasen J, Antoch G, Albers P, et al. Inter-reader agreement of multi-parametric MR imagingfor the detection of prostate cancer: evaluation of a scoringsystem. Rofo 2012;184(10):925-9 [Epub 2012/06/30].
7. Folkman J. What is the evidence that tumors are angio-genesis dependent? J Natl Cancer Inst 1990;82(1):4-6 [Epub1990/01/03]. (Pubitemid 20020880)
8. Padhani AR, Harvey CJ, Cosgrove DO. Angiogenesis imagingin the management of prostate cancer. Nat Clin Pract Urol2005;2(12): 596-607. (Pubitemid 43135243)
9. Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, et al. Assessment of antiangiogenic and antivascu-lar therapeutics using MRI: recommendations for appropriatemethodology for clinical trials. Br J Radiol 2003;76(Spec. No.1):S87-91. (Pubitemid 39530320)
10. Padhani AR, Husband JE. Dynamic contrast-enhanced MRI stud-ies in oncology with an emphasis on quantification, validationand human studies. Clin Radiol 2001;56(8): 607-60.
11. Passe TJ, Bluemke DA, Siegelman SS. Tumor angiogen-esis: tutorial on implications for imaging. Radiology1997;203(3): 593-600. (Pubitemid 27227398)
12. Siegal JA, Yu E, Brawer MK. Topography of neovascularity inhuman prostate carcinoma. Cancer 1995;75(10): 2545-51.
13. Alonzi R, Padhani AR, Allen C. Dynamic contrast enhanced MRIin prostate cancer. Eur J Radiol 2007;63(3): 335-50. (Pubitemid 47321040)
14. Padhani AR, Gapinski CJ, Macvicar DA, Parker GJ, Suckling J, Revell PB, et al. Dynamic contrast enhanced MRI of prostatecancer: correlation with morphology and tumour stage, histo-logical grade and PSA. Clin Radiol 2000;55(2): 99-109. (Pubitemid 32054531)
15. Zelhof B, Lowry M, Rodrigues G, Kraus S, Turnbull L. Descriptionof magnetic resonance imaging-derived enhancement varia-bles in pathologically confirmed prostate cancer and normalperipheral zone regions. BJU Int 2009;104(5):621-7 [Epub2009/03/14].
16. Bigler SA, Deering RE, Brawer MK. Comparison of microscopicvascularity in benign and malignant prostate tissue. Hum Pathol1993;24(2): 220-6. (Pubitemid 23066603)
17. Brawer MK, Deering RE, Brown M, Preston SD, Bigler SA. Pre-dictors of pathologic stage in prostatic carcinoma. The role ofneovascularity. Cancer 1994;73(3): 678-87. (Pubitemid 24046612)
18. Schlemmer HP, Merkle J, Grobholz R, Jaeger T, Michel MS, Werner A, et al. Can pre-operative contrast-enhanced dynamicMR imaging for prostate cancer predict microvessel density inprostatectomy specimens? Eur Radiol 2004;14(2): 309-17. (Pubitemid 38181089)
19. Isebaert S, De Keyzer F, Haustermans K, Lerut E, Roskams T, Roebben I, et al. Evaluation of semi-quantitative dynamiccontrast-enhanced MRI parameters for prostate cancer incorrelation to whole-mount histopathology. Eur J Radiol2012;81(3):e217-22 [Epub 2011/02/26].
20. Hara N, Okuizumi M, Koike H, Kawaguchi M, Bilim V. Dynamiccontrast- enhanced magnetic resonance imaging (DCE-MRI) is auseful modality for the precise detection and staging of earlyprostate cancer. Prostate 2005;62(2): 140-7. (Pubitemid 40096780)
21. Kirkham AP, Emberton M, Allen C. How good is mri at detec-ting and characterising cancer within the prostate? Eur Urol2006;50(6): 1163-75. (Pubitemid 44692933)
22. Jager GJ, Ruijter ET, van de Kaa CA, de la Rosette JJ, Oosterhof GO, Thornbury JR, et al. Dynamic TurboFLASH sub-traction technique for contrast-enhanced MR imaging of theprostate: correlation with histopathologic results. Radiology1997;203(3): 645-52. (Pubitemid 27227409)
23. Muramoto S, Uematsu H, Kimura H, Ishimori Y, Sadato N, Oyama N, et al. Differentiation of prostate cancer from benignprostate hypertrophy using dual-echo dynamic contrast MRimaging. Eur J Radiol 2002;44(1): 52-8. (Pubitemid 35286999)
24. Futterer JJ, Engelbrecht MR, Huisman HJ, Jager GJ, Hulsbergen-van De Kaa CA, Witjes JA, et al. Staging prostatecancer with dynamic contrast-enhanced endorectal MR imagingprior to radical prostatectomy: experienced versus less expe-rienced readers. Radiology 2005;237(2): 541-9. (Pubitemid 41507892)
25. Kim JK, Hong SS, Choi YJ, Park SH, Ahn H, Kim CS, et al. Wash-inrate on the basis of dynamic contrast-enhanced MRI: usefulnessfor prostate cancer detection and localization. J Magn ResonImaging 2005;22(5): 639-46. (Pubitemid 41572716)
26. Kim CK, Park BK, Kim B. Localization of Prostate Cancer Using3 T MRI: comparison of T2-Weighted and Dynamic Contrast-Enhanced Imaging. J Comput Assist Tomogr 2006;30(1): 7-11. (Pubitemid 43052291)
27. Villers A, Puech P, Mouton D, Leroy X, Ballereau C, LemaitreL. Dynamic contrast enhanced, pelvic phased array magneticresonance imaging of localized prostate cancer for predictingtumor volume: correlation with radical prostatectomy findings.J Urol 2006;176(6 Pt 1): 2432-7. (Pubitemid 44665992)
28. Girouin N, Mege-Lechevallier F, Tonina Senes A, Bissery A, Rabilloud M, Marechal JM, et al. Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: is itreasonable? Eur Radiol 2007;17(6): 1498-509. (Pubitemid 46767598)
29. Cheikh AB, Girouin N, Colombel M, Marechal JM, Gelet A, Bis-sery A, et al. Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeatbiopsy. Eur Radiol 2009;19(3):770-8 [Epub 2008/10/18].
30. Cornud F, Beuvon F, Thevenin F, Chauveinc L, Vieillefond A, Descazeaux A, et al. [Quantitative dynamic MRI and localisationof non-palpable prostate cancer]. Prog Urol 2009;19(6):401-13[Epub 2009/05/27. IRM dynamique quantitative et localisationdu cancer de prostate non palpable].
31. Jackson AS, Reinsberg SA, Sohaib SA, Charles-Edwards EM, Jhavar S, Christmas TJ, et al. Dynamic contrast-enhanced MRI for prostate cancer localization. Br J Radiol2009;82(974):148-56 [Epub 2009/01/27].
32. Kozlowski P, Chang SD, Jones EC, Berean KW, Chen H, Goldenberg SL. Combined diffusion-weighted and dynamiccontrast-enhanced MRI for prostate cancer diagnosis - correlation with biopsy and histopathology. J Magn Reson Imag-ing 2006;24(1): 108-13.
33. Haider MA, Chung P, Sweet J, Toi A, Jhaveri K, Menard C, et al. Dynamic contrast-enhanced magnetic resonance imag-ing for localization of recurrent prostate cancer after externalbeam radiotherapy. Int J Radiat Oncol Biol Phys 2008;70(2): 425-30.
34. Yoshizako T, Wada A, Hayashi T, Uchida K, Sumura M, Uchida N, et al. Usefulness of diffusion-weighted imaging anddynamic contrast-enhanced magnetic resonance imaging inthe diagnosis of prostate transition-zone cancer. Acta Radiol2008;49(10):1207-13 [Epub 2008/11/26].
35. Kim CK, Park BK, Park W, Kim SS. Prostate MR imaging at3 T using a phased-arrayed coil in predicting locally recurrentprostate cancer after radiation therapy: preliminary experi-ence. Abdom Imaging 2010;35(2):246-52
36. Kitajima K, Kaji Y, Fukabori Y, Yoshida K, Suganuma N, Sug-imura K. Prostate cancer detection with 3 T MRI: comparisonof diffusion-weighted imaging and dynamic contrast-enhancedMRI in combination with T2-weighted imaging. J Magn ResonImaging 2010;31(3):625-31 [Epub 2010/02/27].
37. Tamada T, Sone T, Higashi H, Jo Y, Yamamoto A, Kanki A, et al. Prostate cancer detection in patients with total serumprostate-specific antigen levels of 4-10 ng/mL: diagnosticefficacy of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging. AJR Am J Roentgenol2011;197(3): 664-70 [Epub 2011/08/25].
38. Schmuecking M, Boltze C, Geyer H, Salz H, Schilling B, Wendt TG, et al. Dynamic MRI and CAD vs. choline MRS: where is thedetection level for a lesion characterisation in prostate cancer?Int J Radiat Biol 2009;85(9):814-24 [Epub 2009/08/25].
39. Sung YS, Kwon HJ, Park BW, Cho G, Lee CK, Cho KS, et al. Prostate cancer detection on dynamic contrast-enhanced MRI:computer-aided diagnosis versus single perfusion parame-ter maps. AJR Am J Roentgenol 2011;197(5):1122-9 [Epub2011/10/25].
40. Puech P, Betrouni N, Viard R, Villers A, Leroy X, Lemaitre L, editors. Prostate cancer computer-assisted diagnosis softwareusing dynamic contrast-enhanced MRI. Engineering in Medicineand Biology Society, EMBS; 2007 [29th Annual InternationalConference of the IEEE].
41. Rosenkrantz AB, Mendrinos S, Babb JS, Taneja SS. Prostatecancer foci detected on multiparametric magnetic resonanceimaging are histologically distinct from those not detected. JUrol 2012;187(6):2032-8 [Epub 2012/04/14].
42. Zechmann CM, Woenne EC, Brix G, Radzwill N, Ilg M, Bachert P, et al. Impact of stroma on the growth, microcirculation, andmetabolism of experimental prostate tumors. Neoplasia (NewYork, NY) 2007;9(1):57-67 [Epub 2007/02/28]. (Pubitemid 46203934)
43. Wang L, Mazaheri Y, Zhang J, Ishill NM, Kuroiwa K, HricakH. Assessment of biological aggressiveness of prostate can-cer: correlation of mr signal intensity with gleason grade afterradical prostatectomy. Radiology 2008;246(1): 168-76. (Pubitemid 350305040)
44. Oto A, Yang C, Kayhan A, Tretiakova M, Antic T, Schmid-Tannwald C, et al. Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitativeMR parameters with Gleason score and tumor angiogenesis. AJRAm J Roentgenol 2011;197(6):1382-90 [Epub 2011/11/24].
45. Kwek JW, Thng CH, Tan PH, Yuen JS, Khoo JB, Quek ST, et al. Phased-array magnetic resonance imaging of the prostate withcorrelation to radical prostatectomy specimens: local experi-ence. Asian J Surg 2004;27(3):219-24 [Discussion 25-26]. (Pubitemid 39094899)
46. Allen DJ, Hindley R, Clovis S, O'Donnell P, Cahill D, Rotten-berg G, et al. Does body-coil magnetic-resonance imaging havea role in the preoperative staging of patients with clinicallylocalized prostate cancer? BJU Int 2004;94(4): 534-8. (Pubitemid 39256475)
47. Puech P, Huglo D, Petyt G, Lemaitre L, Villers A. Imaging oforgan-confined prostate cancer: functional ultrasound, MRI andPET/computed tomography. Curr Opin Urol 2009;19(2):168-76[Epub 2009/02/04].
48. Cornud F, Bellin MF, Portalez D. [MRI and staging evaluation ofprostate cancer]. J Radiol 2006;87(2 Pt 2):228-43 [IRM et biland'extension du cancer de la prostate].
49. Brajtbord JS, Lavery HJ, Nabizada-Pace F, Senaratne P, SamadiDB. Endorectal magnetic resonance imaging has limited clinicalability to preoperatively predict pT3 prostate cancer. BJU Int2011;107(9):1419-24 [Epub 2010/09/02].
50. Hole KH, Axcrona K, Lie AK, Vlatkovic L, Geier OM, Brennhovd B, et al. Routine pelvic MRI using phased-array coil fordetection of extraprostatic tumour extension: accuracy andclinical significance. Eur Radiol 2013;23(4):1158-66 [Epub2012/11/02].
51. Ogura K, Maekawa S, Okubo K, Aoki Y, Okada T, Oda K, et al. Dynamic endorectal magnetic resonance imaging for local stag-ing and detection of neurovascular bundle involvement ofprostate cancer: correlation with histopathologic results. Urol-ogy 2001;57(4): 721-6.
52. Sciarra A, Barentsz J, Bjartell A, Eastham J, Hricak H, Panebianco V, et al. Advances in magnetic resonance imaging:how they are changing the management of prostate cancer. EurUrol 2011;59(6):962-77 [Epub 2011/03/04].
53. Torricelli P, Iadanza M, De Santis M, Pollastri CA, Cesinaro AM, Trentini G, et al. [Magnetic resonance with endorectalcoil in the local staging of prostatic carcinoma. Comparisonwith histologic macrosections in 40 cases]. Radiol Med (Torino)1999;97(6): 491-8.
54. Brown G, Macvicar DA, Ayton V, Husband JE. The role ofintravenous contrast enhancement in magnetic resonanceimaging of prostatic carcinoma. Clin Radiol 1995;50(9): 601-6.
55. Bloch BN, Furman-Haran E, Helbich TH, Lenkinski RE, Degani H, Kratzik C, et al. Prostate cancer: accurate determina-tion of extracapsular extension with high-spatial-resolutiondynamic contrast-enhanced and T2-weighted MR imaging -initial results. Radiology 2007;245(1): 176-85. (Pubitemid 47417801)
56. Bloch BN, Genega EM, Costa DN, Pedrosa I, Smith MP, Kressel HY, et al. Prediction of prostate cancer extra-capsular extension with high spatial resolution dynamiccontrast-enhanced 3-T MRI. Eur Radiol 2012;22(10):2201-10[Epub 2012/06/05].
57. Baccos A, Schiavina R, Zukerman Z, Busato F, Gaudiano C, Sal-izzoni E, et al. [Accuracy of endorectal Magnetic ResonanceImaging (MRI) and Dynamic Contrast Enhanced-MRI (DCE-MRI)in the preoperative local staging of prostate cancer]. Urologia2012;79(2):116-22 [Epub 2012/04/24. Accuratezza della RMN1, 5 T con bobina endorettale e della RMN dinamica (DCE MRI)nella stadiazione preoperatoria dei pazienti affetti da carci-noma prostatico].
58. McMahon CJ, Bloch BN, Lenkinski RE, Rofsky NM. Dynamiccontrast-enhanced MR imaging in the evaluation of patientswith prostate cancer. Magn Reson Imaging Clin N Am2009;17(2):363-83 [Epub 2009/05/02].
59. Renard-Penna R, Roupret M, Comperat E, Ayed A, Coudert M, Mozer P, et al. Accuracy of high resolution (1.5 tesla)pelvic phased array magnetic resonance imaging (MRI) instaging prostate cancer in candidates for radical prosta-tectomy: Results from a prospective study. Urol Oncol2013;31(4):448-54 [Epub 2011/07/22].
60. Nguyen PL, Whittington R, Koo S, Schultz D, Cote KB, Loffredo M, et al. Quantifying the impact of seminal vesicle invasionidentified using endorectal magnetic resonance imaging onPSA outcome after radiation therapy for patients with clini-cally localized prostate cancer. Int J Radiat Oncol Biol Phys2004;59(2):400-5 [Epub 2004/05/18]. (Pubitemid 38622593)
61. Wang L, Hricak H, Kattan MW, Chen HN, Kuroiwa K, Eisenberg HF, et al. Prediction of seminal vesicle invasion in prostate cancer: incremental value of adding endorectal MR imaging tothe Kattan nomogram. Radiology 2007;242(1): 182-8. (Pubitemid 44956023)
62. Panebianco V, Sciarra A, Lisi D, Galati F, Buonocore V, Cata-lano C, et al. Prostate cancer: 1HMRS-DCEMR at 3 T versus[(18)F]choline PET/CT in the detection of local prostatecancer recurrence in men with biochemical progressionafter radical retropubic prostatectomy (RRP). Eur J Radiol2012;81(4):700-8 [Epub 2011/02/19].
63. Boonsirikamchai P, Kaur H, Kuban DA, Jackson E, Hou P, ChoiH. Use of maximum slope images generated from dynamiccontrast-enhanced MRI to detect locally recurrent prostate car-cinoma after prostatectomy: a practical approach. AJR Am JRoentgenol 2012;198(3):W228-36 [Epub 2012/02/24].
64. Casciani E, Polettini E, Carmenini E, Floriani I, Masselli G, Bertini L, et al. Endorectal and dynamic contrast-enhancedMRI for detection of local recurrence after radical prosta-tectomy. AJR Am J Roentgenol 2008;190(5):1187-92[Epub 2008/04/24]. (Pubitemid 351684918)
65. Martino P, Scattoni V, Galosi AB, Consonni P, Trombetta C, Palazzo S, et al. Role of imaging and biopsy to assesslocal recurrence after definitive treatment for prostate car-cinoma (surgery, radiotherapy, cryotherapy, HIFU). Int J Urol2011;29(5):595-605 [Epub 2011/05/10].
66. Moman MR, van den Berg CA, Boeken Kruger AE, Battermann JJ, Moerland MA, van der Heide UA, et al. Focal salvage guidedby T2-weighted and dynamic contrast-enhanced magnetic res-onance imaging for prostate cancer recurrences. Int J RadiatOncol Biol Phys 2010;76(3):741-6 [Epub 2009/10/07].
67. Arumainayagam N, Kumaar S, Ahmed HU, Moore CM, Payne H, Freeman A, et al. Accuracy of multiparametric magnetic res-onance imaging in detecting recurrent prostate cancer afterradiotherapy. BJU Int 2010;106(7):991-7 [Epub 2010/03/17].
68. van Vulpen M, van den Berg CA, Moman MR, van der HeideUA. Difficulties and potential of correlating local recurrences inprostate cancer with the delivered local dose. Radiother Oncol2009;93(2):180-4 [Epub 2009/08/25].
69. Rouviere O, Vitry T, Lyonnet D. Imaging of prostate cancer localrecurrences: why and how? Eur Radiol 2010;20(5):1254-66[Epub 2009/11/19].
70. Eggener SE, Coleman JA. Focal treatment of prostate cancerwith vascular-targeted photodynamic therapy. The ScientificWorld Journal 2008;8:963-73 [Epub 2008/10/07].
71. Scheidler J, Weores I, Brinkschmidt C, Zeitler H, Panzer S, Scharf M, et al. Diagnosis of prostate cancer in patients withpersistently elevated PSA and tumor-negative biopsy in ambu-latory care: performance of MR imaging in a multi-readerenvironment. Rofo 2012;184(2):130-5 [Epub 2012/01/26].
72. Goris Gbenou MC, Peltier A, Addla SK, Lemort M, Bollens R, Larsimont D, et al. Localising prostate cancer: comparison ofendorectal magnetic resonance (MR) imaging and 3D-MR spec-troscopic imaging with transrectal ultrasound-guided biopsy.Urol Int 2012;88(1):12-7 [Epub 2011/10/19].
73. Reiter T, Ritter O, Prince MR, Nordbeck P, Wanner C, Nagel E, et al. Minimizing risk of nephrogenic systemic fibrosis incardiovascular magnetic resonance. J Cardiovasc Magn Reson2012;14:31 [Epub 2012/05/23].
74. Thomsen HS, Morcos SK, Almen T, Bellin MF, Bertolotto M, Bon-gartz G, et al. Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium SafetyCommittee guidelines. Eur Radiol 2013;23(2):307-18 [Epub2012/08/07].
75. Deray G, Rouviere O, Bacigalupo L, Maes B, Hannedouche T, Vrtovsnik F, et al. Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patientswith chronic kidney disease (RESCUE study). Eur Radiol2013;23(5):1250-9 [Epub 2012/12/06].
76. Puech P, Sufana Iancu A, Renard B, Villers A, Lemaitre L. Detec-ting prostate cancer with MRI - why and how. Diagn IntervImaging 2012;93(4): 268-78.
77. Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, et al. ESUR prostate MR guidelines 2012. Eur Radiol2012;22(4): 746-57.